Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
RESEARCH TOOLSreports
SRRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.76 - $46.98
Previous CloseN/A
Volume133.12K
Average Volume (3M)928.58K
Market Cap
$3.46B
Enterprise Value$704.92M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Feb 27, 2025EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding93,614,950
10 Day Avg. Volume760,073
30 Day Avg. Volume928,578
Standard Deviation0.43
R-Squared0.00385
Alpha0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2660.82
Price to Cash Flow (P/CF)-16.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-247.86
Enterprise Value/Ebitda-3.08
Forecast
1Y Price Target
$50.00Price Target Upside27.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Scholar Rock Holding News
PremiumCompany Announcements
Scholar Rock Announces Leadership Changes and Strategic Growth
PremiumCompany Announcements
Scholar Rock Highlights Apitegromab Progress at JP Morgan
---
Bulls Say, Bears Say
Bulls Say
Clinical ResultsPositive topline results were announced from the SAPPHIRE trial, showing consistent and clinically meaningful benefits for apitegromab in non-ambulatory patients with spinal muscular atrophy.
Market OpportunityThe SMA market opportunity could be larger than anticipated given the removal of this competitive overhang.
Regulatory ProgressScholar Rock remains on track to submit a U.S. Biologics License Application and a European Union marketing authorization application in the first quarter of 2025.
Bears Say
Competitor DynamicsInvestors are a bit nervous into BHVN upcoming Phase III SMA taldefgrobep alfa myostatin data.
Market ReactionIf BHVN is positive and 'similar' to SRRK, the latter could trade down a bit but should bounce back given the market is significant.
Market VolatilityThe stock is up approximately 30% pre-market.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SRRK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was $6.76 and its highest was $46.98 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Scholar Rock Holding Corp’s market cap is $3.46B.
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is Feb 27, 2025 which is in 6 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Nov 12, 2024. The company reported -$0.66 earnings per share for the quarter, missing the consensus estimate of -$0.58 by -$0.08.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -0.6.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 93,614,950 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -$0.66 in its last earnings report, missing expectations of -$0.58. Following the earnings report the stock price went down -5.293%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Currently, no hedge funds are holding shares in SRRK
---
Scholar Rock Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.00 (27.71% Upside)
$50.00 (27.71% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 179.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $82.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
139.50%
12-Months-Change
Fundamentals
Return on Equity
-183.07%
Trailing 12-Months
Asset Growth
-28.54%
Trailing 12-Months
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corp. is a biopharmaceutical company, which engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
---
SRRK Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress and success in clinical trials, financial strength, and strategic planning for regulatory and commercial milestones. While there is competitive pressure in the obesity market, the overall outlook is positive with robust clinical data and strong financial backing.Read More>---
SRRK Stock 12 Month Forecast
Average Price Target
$50.00
▲(27.71% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Best Analysts Covering SRRK
1 Year
1 Year Success Rate
8/8 ratings generated profit
1 Year Average Return
+187.24%
assigned a buy rating 4 months ago
Copying Allison Bratzel's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +187.24% per trade.
---